Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24364599 | 0.90 | PTPN11 (0.44) | MAPKAPK2MAPK14MAP4K4RORCCYP17A1 | |
| SCHEMBL30469774 | 0.90 | PTPN11 (0.44) | MAPKAPK2MAPK14MAP4K4RORCCYP17A1 | |
| SCHEMBL31430391 | 0.87 | MAPT (0.44) | RORC | |
| SCHEMBL31430242 | 0.87 | MAPT (0.44) | RORC | |
| SCHEMBL29477860 | 0.86 | MAPKAPK2 (0.37) | MAPKAPK2AURKARPS6KB1MAP4K4RORC | |
| SCHEMBL29081978 | 0.86 | MAPKAPK2 (0.37) | MAPKAPK2AURKARPS6KB1MAP4K4RORC | |
| SCHEMBL29081276 | 0.83 | AR (0.36) | MAPKAPK2MAPK14RORCSYK | |
| SCHEMBL24364867 | 0.82 | MAPKAPK2 (0.41) | MAPKAPK2MAPK14MAP4K4CYP17A1PRMT1 | |
| SCHEMBL31430396 | 0.82 | MAPKAPK2 (0.41) | MAPKAPK2MAPK14MAP4K4CYP17A1PRMT1 | |
| SCHEMBL32689297 | 0.81 | MAPKAPK2 (0.35) | MAPKAPK2MAPK14AURKARPS6KB1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPKAPK2 4853/4885MAPK14 4784/4885AURKA 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.